Table 3.
MACE rates and components within the study cohort over 3-years of follow-up
| Mortality | MACE | Non-fatal MI | Repeat revascularization | |
|---|---|---|---|---|
| Total study cohort (n = 1258) | ||||
| 1 y | 55 (4.4) | 305 (24.2) | 169 (13.4) | 81 (6.4) |
| 2 y | 109 (8.7) | 482 (38.3) | 261 (20.7) | 112 (8.9) |
| 3 y | 152 (12.1) | 624 (49.6) | 334 (26.6) | 138 (11.0) |
| FFR-guided treatment arm (n = 629) | ||||
| 1 y | 24 (3.8) | 145 (23.1) | 87 (13.8) | 34 (5.4) |
| 2 y | 46 (7.3) | 230 (36.6) | 140 (22.3) | 47 (7.5) |
| 3 y | 64 (10.2) | 300 (47.7) | 174 (27.7) | 62 (9.9) |
| Angiography-guided treatment arm (n = 629) | ||||
| 1 y | 31 (4.9) | 160 (25.4) | 82 (13.0) | 47 (7.5) |
| 2 y | 63 (10.0) | 252 (40.1) | 121 (19.2) | 71 (11.3) |
| 3 y | 88 (14.5) | 324 (51.5) | 160 (25.4) | 76 (12.1) |
MACE major adverse cardiovascular events, MI myocardial infarction, n number, y year